
Sol-Gel Technologies (SLGL) Stock Forecast & Price Target
Sol-Gel Technologies (SLGL) Analyst Ratings
Bulls say
Sol-Gel Technologies Ltd is positioned favorably in the dermatology sector with its promising product pipeline, notably SGT-610, which is anticipated to be the first preventive treatment for basal cell carcinoma (BCC) lesions in Gorlin syndrome patients, a market estimated at around 11,000 individuals in the U.S. If approved, SGT-610 could potentially reach peak annual revenues exceeding $300 million, with expectations for annual sales surpassing $270 million by 2035. Additionally, the company's recent licensing agreement with Searchlight, aimed at obtaining Canadian regulatory approval for their EPSOLAY product, further underscores its strategic advancement in commercializing innovative treatments.
Bears say
Sol-Gel Technologies faces significant challenges that contribute to a negative outlook on its stock, primarily due to the slower-than-anticipated enrollment for its clinical trials, notably pushing the guidance for SGT-610's pivotal trial to 1H25. The discontinuation of the SGT-210 program for Darier disease, coupled with disappointing results from the topical erlotinib clinical study, underscores operational setbacks that may hinder the company's growth prospects. Additionally, the company has introduced a reverse stock split, raising concerns about possible medium- to long-term dilution risks, further complicating Sol-Gel's financial stability and future market performance.
This aggregate rating is based on analysts' research of Sol-Gel Technologies and is not a guaranteed prediction by Public.com or investment advice.
Sol-Gel Technologies (SLGL) Analyst Forecast & Price Prediction
Start investing in Sol-Gel Technologies (SLGL)
Order type
Buy in
Order amount
Est. shares
0 shares